Tackling dengue fever: Current status and challenges

Taoufik Nedjadi, Sherif El-Kafrawy, Sayed S Sohrab, Philippe Desprès, Ghazi Damanhouri, Esam Azhar, Taoufik Nedjadi, Sherif El-Kafrawy, Sayed S Sohrab, Philippe Desprès, Ghazi Damanhouri, Esam Azhar

Abstract

According to recent statistics, 96 million apparent dengue infections were estimated worldwide in 2010. This figure is by far greater than the WHO prediction which indicates the rapid spread of this disease posing a growing threat to the economy and a major challenge to clinicians and health care services across the globe particularly in the affected areas.This article aims at bringing to light the current epidemiological and clinical status of the dengue fever. The relationship between genetic mutations, single nucleotide polymorphism (SNP) and the pathophysiology of disease progression will be put into perspective. It will also highlight the recent advances in dengue vaccine development.Thus far, a significant progress has been made in unraveling the risk factors and understanding the molecular pathogenesis associated with the disease. However, further insights in molecular features of the disease and the development of animal models will enormously help improving the therapeutic interventions and potentially contribute to finding new preventive measures for population at risk.

Figures

Fig. 1
Fig. 1
WHO dengue case classification (Adopted from; Dengue Guidelines for diagnosis, treatment, prevention and control, New edn. Geneva: WHO; 2009)

References

    1. Tang KF, Ooi EE. Diagnosis of dengue: An update. Expert Rev Anti Infect Ther. 2012;10(8):895–907. doi: 10.1586/eri.12.76.
    1. WHO: Dengue. Guidelines for diagnosis, treatment prevention and control, Geneva, World Health Organization, 2009, WHO/HTM/NTD/DEN/2009. ()
    1. Bhatt S, Gething PW, Brady OJ, Messina JP, Farlow AW, Moyes CL, et al. The global distribution and burden of dengue. Nature. 2013;496(7446):504–7. doi: 10.1038/nature12060.
    1. Malavige GN, Fernando S, Fernando DJ, Seneviratne SL. Dengue viral infections. Postgrad Med J. 2004;80:588–601. doi: 10.1136/pgmj.2004.019638.
    1. Madani TA, Abuelzein EL-TM, Al-Bar HM, Azhar EI, Kao M, Alshoeb HO, et al. Outbreak of viral hemorrhagic fever caused by dengue virus type 3 in Al-Mukalla, Yemen. BMC Infect Dis. 2013;14(13):136. doi: 10.1186/1471-2334-13-136.
    1. Azhar EI, Hashem AM, El-Kafrawy SA, Abol-Ela S, Abd-Alla AM, Sohrab SS, et al. Complete genome sequencing and phylogenetic analysis of dengue type 1 virus isolated from Jeddah, Saudi Arabia. Virol J. 2015;12:1. doi: 10.1186/s12985-014-0235-7.
    1. Normile D. Surprising new dengue virus throws a spanner in disease control efforts. Science. 2013;342(6157):415. doi: 10.1126/science.342.6157.415.
    1. Angel B, Joshi V. Distribution and seasonality of vertically transmitted dengue viruses in Aedes mosquitoes in arid and semi-arid areas of Rajasthan. India J Vector Borne Dis. 2008;45:56–59.
    1. Martins V, Alencar C, Kamimura M, de Carvalho Arau’jo F, De Simone S, Dutra R, et al. Occurrence of natural vertical transmission of dengue-2 and dengue-3 viruses in Aedes aegypti and Aedes albopictus in Fortaleza, Ceara’, Brazil. PLoS One. 2012;7(7):e41386. doi: 10.1371/journal.pone.0041386.
    1. Günther J, Martinez-Munoz JP, Pérez-Ishiwara DG, Salas-Benito J. Evidence of vertical transmission of dengue virus in two endemic localities in the State of Oaxaca, Mexico. Intervirology. 2007;50:347–352. doi: 10.1159/000107272.
    1. Mulyatno KC, Yamanaka A, Yotopranoto S, Konishi E. Vertical transmission of dengue virus in Aedes aegypti collected in Surabaya, Indonesia, during 2008–2011. Jpn J Infect Dis. 2012;65:274–276. doi: 10.7883/yoken.65.274.
    1. Phongsamart W, Yoksan S, Vanaprapa N, Chokephaibulkit K. Dengue virus infection in late pregnancy and transmission to the infants. Pediatr Infect Dis J. 2008;27(6):500–4. doi: 10.1097/INF.0b013e318167917a.
    1. Kariyawasam S, Senanayake H. Dengue infections during pregnancy: Case series from a tertiary care hospital in Sri Lanka. J Infect Dev Ctries. 2010;4(11):767–775. doi: 10.3855/jidc.908.
    1. Barthel A, Gourinat A-C, Cazorla C, Joubert C, Dupont-Rouzeyrol M, Descloux E. Breast milk as a possible route of vertical transmission of dengue virus? Clin Infect Dis. 2013;57(3):415–7. doi: 10.1093/cid/cit227.
    1. Chan M, Johansson AM. The incubation periods of dengue viruses. PLoS One. 2012;7(11):e50972. doi: 10.1371/journal.pone.0050972.
    1. Guha-Sapir D, Schimmer B. Dengue fever new paradigms for a changing epidemiology. Emerg Themes Epidemiol. 2005;2:1–10. doi: 10.1186/1742-7622-2-1.
    1. Khan NA, Azhar EI, El-Fiky S, Madani HH, Abuljadial MA, Ashshi AM, et al. Clinical profile and outcome of hospitalized patients during first outbreak of dengue in Makkah, Saudi Arabia. Acta Trop. 2008;105(1):39–44. doi: 10.1016/j.actatropica.2007.09.005.
    1. Ooi EE, Goh KT, Gubler JD. Dengue prevention and 35 years of vector control in Singapore. Emerg Infect Dis. 2006;12(6):887–893. doi: 10.3201/eid1206.051210.
    1. Simmons CP, Farrar JJ, Vinh CN, Wills B. Dengue. N Engl J Med. 2012;366:1423–1432. doi: 10.1056/NEJMra1110265.
    1. Low JG, Ooi EE, Tolfvenstam T, Leo YS, Hibberd ML, Ng LC, et al. Early dengue infection and outcome study (EDEN) - study design and preliminary findings. Ann Acad Med Singapore. 2006;35(11):783–9.
    1. Wichmann O, Jelinek T. Dengue in travelers. A Review. J Travel Med. 2004;11:161–170. doi: 10.2310/7060.2004.18503.
    1. Peeling RW, Artsob H, Pelegrino JL, Buchy P, Cardosa MJ, Devi S, et al. Evaluation of diagnostic tests: Dengue. Nat Rev Microbiol. 2010;8(12 Suppl):S30–8. doi: 10.1038/nrmicro2459.
    1. Schexneider KI, Reedy EA. Thrombocytopenia in dengue fever. Curr Hematol Rep. 2005;4(2):145–8.
    1. Martina BE, Koraka P, Osterhaus AD. Dengue virus pathogenesis. Integr View Clin Microbiol Rev. 2009;22(4):564–581. doi: 10.1128/CMR.00035-09.
    1. Noisakran S, Kulkanya C, Pucharee S, Nattawat O, Hui-Mien H, Francois V, et al. A re-evaluation of the mechanisms leading to dengue hemorrhagic fever. Ann NY Acad Sci. 2009;1171:E24–E35. doi: 10.1111/j.1749-6632.2009.05050.x.
    1. Marques N, Gan VC, Leo YS. Dengue myocarditis in Singapore: Two case reports. Infection. 2013;41(3):709–14. doi: 10.1007/s15010-012-0392-9.
    1. Misra UK, Kalita J, Syam UK, Dhole TN. Neurological manifestations of dengue virus infection. J Neurol Sci. 2006;244(1–2):117–22. doi: 10.1016/j.jns.2006.01.011.
    1. Gubler DJ. Epidemic dengue/dengue hemorrhagic fever as a public health, social and economic problem in the 21st century. Trends Microbiol. 2002;10(2):3–100. doi: 10.1016/S0966-842X(01)02288-0.
    1. Low GJ, Ong A, Tan LK, Shera C, Angelia C, Wen YL, et al. The early clinical features of dengue in adults: Challenges for early clinical diagnosis. PLoS Negl Trop Dis. 2011;5(5):e1191. doi: 10.1371/journal.pntd.0001191.
    1. Alcon-LePoder S, Sivard P, Drouet MT, Talarmin A, Rice C, Flamand M. Secretion of flaviviral non-structural protein NS1: From diagnosis to pathogenesis. Novartis Found Symp. 2006;277:233–47. doi: 10.1002/0470058005.ch17.
    1. Zanluca C, Mazzarotto GA, Bordignon J, Duarte Dos Santos CN. Development, characterization and application of monoclonal antibodies against Brazilian dengue virus isolates. PLoS One. 2014;9(11):e110620. doi: 10.1371/journal.pone.0110620.
    1. Dos Santos HW, Poloni TR, Souza KP, Muller VD, Tremeschin F, Nali LC, et al. A simple one-step real-time RT-PCR for diagnosis of dengue virus infection. J Med Virol. 2008;80(8):1426–33. doi: 10.1002/jmv.21203.
    1. Shu PY, Huang JH. Current advances in dengue diagnosis. Clin Vaccine Immunol. 2004;11(4):642–650. doi: 10.1128/CDLI.11.4.642-650.2004.
    1. Cordeiro MT, Braga-Neto U, Nogueira RR, Marques TE. Reliable classifier to differentiate primary and secondary acute dengue infection based on IgG ELISA. PloS One. 2009;4(4):e4945. doi: 10.1371/journal.pone.0004945.
    1. Vannberg FO, Chapman SJ, Hill AV. Human genetic susceptibility to intracellular pathogens. Immunol Rev. 2011;240(1):105–16. doi: 10.1111/j.1600-065X.2010.00996.x.
    1. Lan TN, Hirayama K. Host genetic susceptibility to severe dengue infection. Trop Med Health. 2011;39(4):73–81. doi: 10.2149/tmh.2011-S08.
    1. Platt KB, Linthicum KJ, Myint KS, Innis BL, Lerdthusnee K, Vaughn DW. Impact of dengue virus infection on feeding behavior of Aedes aegypti. Am J Trop Med Hyg. 1997;57(2):119–25.
    1. Sim S, Ramirez JL, Dimopoulos G. Dengue virus infection of the Aedes aegypti salivary gland and chemosensory apparatus induces genes that modulate infection and blood-feeding behavior. PLoS Pathog. 2012;8(3):e1002631. doi: 10.1371/journal.ppat.1002631.
    1. Chang C, Shen WK, Wang TT, Lin YH, Hsu EL, Dai SM. A novel amino acid substitution in a voltage gated sodium channel is associated with knockdown resistance to permethrin in Aedes aegypti. Insect Biochem Mol Biol. 2009;39(4):272–8. doi: 10.1016/j.ibmb.2009.01.001.
    1. Kawada H, Higa Y, Komagata O, Kasai S, Tomita T, Thi Yen N, et al. Widespread distribution of newly found point mutation in voltage-gated sodium channel in pyrethroid-resistant Aedes aegypti populations in Vietnam. PLoS Negl Trop Dis. 2009;3(10):e527. doi: 10.1371/journal.pntd.0000527.
    1. Stenhouse SA, Plernsub S, Yanola J, Lumjuan N, Dantrakool A, Choochote W, et al. Detection of the V1016G mutation in the voltage-gated sodium channel gene of Aedes aegypti (Diptera: Culicidae) by allele-specific PCR assay, and its distribution and effect on deltamethrin resistance in Thailand. Parasit Vectors. 2013;6(1):253. doi: 10.1186/1756-3305-6-253.
    1. De la C Sierra B, Kourí G, Guzmán MG. Race: A risk factor for dengue hemorrhagic fever. Arch Virol. 2007;152(3):533–42. doi: 10.1007/s00705-006-0869-x.
    1. García G, Sierra B, Pérez AB, Aguirre E, Rosado I, Gonzalez N, et al. Asymptomatic dengue infection in a Cuban population confirms the protective role of the RR variant of the FcgammaRIIa polymorphism. Am J Trop Med Hyg. 2010;82(6):1153–6. doi: 10.4269/ajtmh.2010.09-0353.
    1. Sakuntabhai A, Turbpaiboon C, Casadémont I, Chuansumrit A, Lowhnoo T, Kajaste-Rudnitski A, et al. A variant in the CD209 promoter is associated with severity of the disease. Nat Genet. 2005;37(5):507–13. doi: 10.1038/ng1550.
    1. Chaturvedi U, Nagar R, Shrivastava R. Dengue and dengue haemorrhagic fever: Implications of host genetics. FEMS Immunol Med Microbiol. 2006;47(2):155–66. doi: 10.1111/j.1574-695X.2006.00058.x.
    1. Soundravally R, Hoti SL. Polymorphisms of the TAP 1 and 2 gene may influence clinical outcome of primary dengue viral infection. Scand J Immunol. 2008;67:618–625. doi: 10.1111/j.1365-3083.2008.02109.x.
    1. Othman S, Rahman NA, Yusof R. All serotypes of dengue virus induce HLA-A2 major histocompatibility complex class I promoter activity in human liver cells. Trans R Soc Trop Med Hyg. 2010;104(12):806–8. doi: 10.1016/j.trstmh.2010.07.004.
    1. Bahram S, Arnold D, Bresnahan M, Strominger JL, Spies T. Two putative subunits of a peptide pump encoded in the human major histocompatibility complex class II region. Proc Natl Acad Sci U S A. 1991;88:10094–8. doi: 10.1073/pnas.88.22.10094.
    1. Alagarasu K, Honap T, Damle IM, Mulay AP, Shah PS, Cecilia D. Polymorphisms in the oligoadenylate synthetase gene cluster and its association with clinical outcomes of dengue virus infection. Infect Genet Evol. 2013;14:390–5. doi: 10.1016/j.meegid.2012.12.021.
    1. Boonnak K, Kaitlyn MD, Gina CD, Tassaneetrithep B, Marovich AM. Cell type specificity and host genetic polymorphisms influence antibody-dependent enhancement of dengue virus infection. J Virol. 2011;85(4):1671–1683. doi: 10.1128/JVI.00220-10.
    1. Peurta-Guardo H, de la Cruz Hernendez SI, Rosales VH, Ludert JE, del Angel RM. The 1a, 25-dihydroxy-vitamin D3 reduces dengue virus infection in human myelomonocyte (U937) and hepatic (Huh-7) cell lines and cytokine production in the infected monocytes. Antiviral Res. 2012;94(1):57–61. doi: 10.1016/j.antiviral.2012.02.006.
    1. Alagarasu K, Honap T, Mulay AP, Bachal RV, Shah PS, Cecilia D. Association of vitamin D receptor gene polymorphisms with clinical outcomes of dengue virus infection. Hum Immunol. 2012;73(11):1194–9. doi: 10.1016/j.humimm.2012.08.007.
    1. Khor CC, Chau TN, Pang J, Davila S, Long HT, Ong RT, et al. Genome-wide association study identifies susceptibility loci for dengue shock syndrome at MICB and PLCE1. Nat Genet. 2011;43(11):1139–41. doi: 10.1038/ng.960.
    1. Steinle A, Li P, Morris DL, Groh V, Lanier LL, Strong RK, et al. Interactions of human NKG2D with its ligands MICA, MICB, and homologs of the mouse RAE-1 protein family. Immunogenetics. 2001;53:279–287. doi: 10.1007/s002510100325.
    1. Lang PA, Lang KS, Xu HC, Grusdat M, Parish IA, Recher M, et al. Natural killer cell activation enhances immune pathology and promotes chronic infection by limiting CD8+ T-cell immunity. Proc Natl Acad Sci USA. 2012;109(4):1210–5.
    1. Whitehorn J, Chau TN, Nguyet NM, Kien DT, Quyen NT, Trung DT, et al. Genetic variants of MICB and PLCE1 and associations with non-severe dengue. PLoS One. 2013;8(3):e59067. doi: 10.1371/journal.pone.0059067.
    1. Fink J, Gu F, Ling L, Tolfvenstam T, Olfat F, Chin KC, et al. Host gene expression profiling of dengue virus infection in cell lines and patients. PLoS Negl Trop Dis. 2007;1(2):e86. doi: 10.1371/journal.pntd.0000086.
    1. Hoh BP, Umi-Shakina H, Zuraihan Z, Zaiharina MZ, Rafidah-Hanim S, Mahiran M, et al. Common variants of chemokine receptor gene CXCR3 and its ligands CXCL10 and CXCL11 associated with vascular permeability of dengue infection in peninsular Malaysia. Hum Immunol. 2015;76(6):421–6. doi: 10.1016/j.humimm.2015.03.019.
    1. Tang NL, Chan PK, Wong CK, To KF, Wu AK, et al. Early enhanced expression of interferon-inducible protein-10 (CXCL-10) and other chemokines predicts adverse outcome in severe acute respiratory syndrome. Clin Chem. 2005;51:2333–2340. doi: 10.1373/clinchem.2005.054460.
    1. Zhang B, Chan YK, Lu B, Diamond MS, Klein RS. CXCR3 mediates region-specific antiviral T cell trafficking within the central nervous system during West Nile virus encephalitis. J Immunol. 2008;180:2641–2649. doi: 10.4049/jimmunol.180.4.2641.
    1. Cerny D, Haniffa M, Shin A, Bigliardi P, Tan BK, Lee B, et al. Selective susceptibility of human skin antigen presenting cells to productive dengue virus infection. PLoS Pathog. 2014;10(12):e1004548. doi: 10.1371/journal.ppat.1004548.
    1. Briant L, Desprès P, Choumet V, Missé D. Role of skin immune cells on the host susceptibility to mosquito-borne viruses. Virology. 2014;464–465:26–32. doi: 10.1016/j.virol.2014.06.023.
    1. McArthur MA, Sztein MB, Edelman R. Dengue vaccines: Recent developments, ongoing challenges and current candidates. Expert Rev Vaccines. 2013;12(8):933–53. doi: 10.1586/14760584.2013.815412.
    1. Hombach J. Vaccines against dengue: A review of current candidate vaccines at advanced development stages. Rev Panam Salud Publica. 2007;21(4):254–260. doi: 10.1590/S1020-49892007000300011.
    1. Whitehead SS, Blaney JE, Durbin AP, Murphy BR. Prospects for a dengue virus vaccine. Nat Rev Microbiol. 2007;5(7):518–528. doi: 10.1038/nrmicro1690.
    1. Webster DP, Farrar J, Rowland-Jones S. Progress towards a dengue vaccine. Lancet Infect Dis. 2009;9(11):678–687. doi: 10.1016/S1473-3099(09)70254-3.
    1. Raviprakash K, Defang G, Burgess T, Porter K. Advances in dengue vaccine development. Hum Vaccin. 2009;5(8):520–528. doi: 10.4161/hv.5.8.9008.
    1. Coller BA, Clements DE. Dengue vaccines: Progress and challenges. Curr Opin Immunol. 2011;23(3):391–8. doi: 10.1016/j.coi.2011.03.005.
    1. Guy B, Barrere B, Malinowski C, Saville M, Teyssou R, Lang J. From research to phase III: Preclinical, industrial and clinical development of the Sanofi Pasteur tetravalent dengue vaccine. Vaccine. 2011;29(42):7229–7241. doi: 10.1016/j.vaccine.2011.06.094.
    1. Mantel N, Girerd Y, Geny C, Bernard I, Pontvianne J, Lang J, et al. Genetic stability of a dengue vaccine based on chimeric yellow fever/dengue viruses. Vaccine. 2011;29(38):6629–6635. doi: 10.1016/j.vaccine.2011.06.101.
    1. Sabchareon A, Wallace D, Sirivichayakul C, Limkittikul K, Chanthavanich P, Suvannadabba S, et al. Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: A randomised, controlled phase 2b trial. Lancet. 2012;380(9853):1559–67. doi: 10.1016/S0140-6736(12)61428-7.
    1. Capeding RZ, Luna IA, Bomasang E, Lupisan S, Lang J, Forrat R, et al. Live-attenuated, tetravalent dengue vaccine in children, adolescents and adults in a dengue endemic country: Randomized controlled phase I trial in the Philippines. Vaccine. 2011;29(22):3863–72. doi: 10.1016/j.vaccine.2011.03.057.
    1. Huu TN, Quang LC, Vu TQH, Forrat R, Lang J, et al. Safety and immunogenicity of recombinant, live attenuated tetravalent dengue vaccine (CYD- TDV) in healthy Vietnamese adults and children. J Vaccines Vaccin. 2012;3:162.
    1. Capeding MR, Tran NH, Hadinegoro SR, Ismail HI, Chotpitayasunondh T, Chua MN, et al. Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: A phase 3, randomised, observer-masked, placebo-controlled trial. Lancet. 2014;384(9951):1358–65. doi: 10.1016/S0140-6736(14)61060-6.
    1. Villar L, Dayan GH, Arredondo-García JL, Rivera DM, Cunha R, Deseda C, et al. CYD15 study group. Efficacy of a tetravalent dengue vaccine in children in Latin America. N Engl J Med. 2015;372(2):113–23. doi: 10.1056/NEJMoa1411037.
    1. Men R, Bray M, Clark D, Chanock RM, Lai CJ. Dengue type 4 virus mutants containing deletions in the 3’ noncoding region of the RNA genome: Analysis of growth restriction in cell culture and altered viremia pattern and immunogenicity in rhesus monkeys. J Virol. 1996;70(6):3930–7.
    1. Troyer JM, Hanley KA, Whitehead SS, Strickman D, Karron RA, Durbin AP, et al. A live attenuated recombinant dengue-4 virus vaccine candidate with restricted capacity for dissemination in mosquitoes and lack of transmission from vaccinees to mosquitoes. Am J Trop Med Hyg. 2001;65(5):414–9.
    1. Durbin AP, Whitehead SS, McArthur J, Perreault JR, Blaney JE, Jr, Thumar B, et al. rDEN4delta30, a live attenuated dengue virus type 4 vaccine candidates, is safe, immunogenic, and highly infectious in healthy adult volunteers. J Infect Dis. 2005;191(5):710–718. doi: 10.1086/427780.
    1. Durbin AP, McArthur J, Marron JA, Blaney JE, Jr, Thumar B, Wanionek K, et al. The live attenuated dengue serotype 1 vaccine rDEN1Delta30 is safe and highly immunogenic in healthy adult volunteers. Hum Vaccin. 2006;2(4):167–173. doi: 10.4161/hv.2.4.2944.
    1. Brandler S, Lucas-Hourani M, Moris A, Frenkiel M-P, Combredet C, et al. Pediatric measles vaccine expressing a dengue antigen induces durable serotype-specific neutralizing antibodies to dengue virus. PLoS Negl Trop Dis. 2007;1(3):e96. doi: 10.1371/journal.pntd.0000096.
    1. Brandler S, Ruffie C, Najburg V, Frenkiel MP, Bedouelle H, Desprès P, et al. Pediatric measles vaccine expressing a dengue tetravalent antigen elicitsneutralizing antibodies against all four dengue viruses. Vaccine. 2010;28(41):6730–9. doi: 10.1016/j.vaccine.2010.07.073.
    1. Danko JR, Beckett CG, Porter KR. Development of dengue DNA vaccines. Vaccine. 2011;29(42):7261–7266. doi: 10.1016/j.vaccine.2011.07.019.
    1. Beckett CG, Tjaden J, Burgess T, Danko JR, Tamminga C, Simmons M, et al. Evaluation of a prototype dengue-1 DNA vaccine in a phase 1 clinical trial. Vaccine. 2011;29(5):960–968. doi: 10.1016/j.vaccine.2010.11.050.
    1. Porter KR, Ewing D, Chen L, Wu SJ, Hayes CG, Ferrari M, et al. Immunogenicity and protective efficacy of a vaxfectin-adjuvanted tetravalent dengue DNA vaccine. Vaccine. 2012;30(2):336–341. doi: 10.1016/j.vaccine.2011.10.085.
    1. Lima DM, de Paula SO, França RF, Palma PV, Morais FR, Gomes-Ruiz AC, et al. A DNA vaccine candidate encoding the structural prM/E proteins elicits a strong immune response and protects mice against dengue-4 virus infection. Vaccine. 2011;29(4):831–838. doi: 10.1016/j.vaccine.2010.10.078.
    1. Costa SM, Yorio AP, Gonçalves AJ, Vidale MM, Costa EC, Mohana-Borges R, et al. Induction of a protective response in mice by the dengue virus NS3 protein using DNA vaccines. PLoS One. 2011;6(10):e25685. doi: 10.1371/journal.pone.0025685.
    1. Zheng Q, Fan D, Gao N, Chen H, Wang J, Ming Y, et al. Evaluation of a DNA vaccine candidate expressing prM-E-NS1 antigens of dengue virus serotype 1 with or without granulocyte-macrophage colony-stimulating factor (GM-CSF) in immunogenicity and protection. Vaccine. 2011;29(4):763–71. doi: 10.1016/j.vaccine.2010.11.014.
    1. Putnak R, Barvir DA, Burrous JM, Dubois DR, D’Andrea VM, Hoke CH, et al. Development of a purified, inactivated, dengue-2 virus vaccine prototype in Vero cells: Immunogenicity and protection in mice and rhesus monkeys. J Infect Dis. 1996;174(6):1176–84. doi: 10.1093/infdis/174.6.1176.
    1. Putnak R, Barvir DA, Burrous JM, Dubois DR, D’Andrea VM, Hoke CH, et al. Immunogenic and protective response in mice immunized with a purified, inactivated, Dengue–2 virus vaccine prototype made in fetal rhesus lung cells. Am J Trop Med Hyg. 1996;55(5):504–510.
    1. Srivastava AK, Putnak JR, Lee SH, Hong SP, Moon SB, Barvir DA, et al. A purified inactivated Japanese encephalitis virus vaccine made in Vero cells. Vaccine. 2001;19(31):4557–4565. doi: 10.1016/S0264-410X(01)00208-0.
    1. Eckels KH, Putnak R. Formalin-inactivated whole virus and recombinant subunit flavivirus vaccines. Adv Virus Res. 2003;61:395–418. doi: 10.1016/S0065-3527(03)61010-9.
    1. Kaltenböck A, Dubischar-Kastner K, Eder G, Jilg W, Klade C, et al. Safety and immunogenicity of concomitant vaccination with the cell-culture based Japanese Encephalitis vaccine IC51 and the hepatitis A vaccine HAVRIX1440 in healthy subjects: A single-blind, randomized, controlled Phase 3 study. Vaccine. 2009;27(33):4483–9. doi: 10.1016/j.vaccine.2009.05.034.
    1. Van Gessel Y, Klade CS, Putnak R, Formica A, Krasaesub S, Spruth M, et al. Correlation of protection against Japanese encephalitis virus and JE vaccine (IXIARO) induced neutralizing antibody titers. Vaccine. 2011;29(35):5925–31. doi: 10.1016/j.vaccine.2011.06.062.
    1. Coller BA, Barrett AD, Thomas SJ. The development of Dengue vaccines. Introduction. Vaccine. 2011;29(42):7219–7220. doi: 10.1016/j.vaccine.2011.06.057.
    1. Clements DE, Coller BA, Lieberman MM, Ogata S, Wang G, Harada KE, et al. Development of a recombinant tetravalent dengue virus vaccine: Immunogenicity and efficacy studies in mice and monkeys. Vaccine. 2010;28(15):2705–2715. doi: 10.1016/j.vaccine.2010.01.022.
    1. Osorio JE, Huang CY, Kinney RM, Stinchcomb DT. Development of DENVax: a chimeric dengue-2 PDK-53-based tetravalent vaccine for protection against dengue fever. Vaccine. 2011;29(42):7251–60. doi: 10.1016/j.vaccine.2011.07.020.
    1. Brewoo JN, Kinney RM, Powell TD, Arguello JJ, Silengo SJ, Partidos CD, et al. Immunogenicity and efficacy of chimeric dengue vaccine (DENVax) formulations in interferon-deficient AG129 mice. Vaccine. 2012;30(8):1513–1520. doi: 10.1016/j.vaccine.2011.11.072.
    1. Durbin AP, Whitehead SS. Next-generation dengue vaccines: Novel Strategies currently under development. Viruses. 2011;3(10):1800–1814. doi: 10.3390/v3101800.
    1. Schmitz J, Roehrig J, Barrett A, Hombach J. Next generation dengue vaccines: A review of candidates in preclinical development. Vaccine. 2011;29(42):7276–84. doi: 10.1016/j.vaccine.2011.07.017.
    1. Block OK, Rodrigo WW, Quinn M, Jin X, Rose RC, Schlesinger JJ. A tetravalent recombinant dengue domain III protein vaccine stimulates neutralizing and enhancing antibodies in mice. Vaccine. 2010;28(51):8085–94. doi: 10.1016/j.vaccine.2010.10.004.
    1. Etemad B, Batra G, Raut R, Dahiya S, Khanam S, Swaminathan S, et al. An envelope domain III–based chimeric antigen produced in pichia pastoris elicits Neutralizing antibodies against all four dengue virus serotypes. Am J Trop Med Hyg. 2008;79(3):353–363.
    1. Kochel TJ, Raviprakash K, Hayes CG, Watts DM, Russell KL, Gozalo AS, et al. A dengue virus serotype-1 DNA vaccine induces virus neutralizing antibodies and provides protection from viral challenge in Aotus monkeys. Vaccine. 2000;18(27):3166–73. doi: 10.1016/S0264-410X(00)00105-5.
    1. Raviprakash K, Kochel TJ, Ewing D, Simmons M, Phillips I, Hayes CG, et al. Immunogenicity of dengue virus type 1 DNA vaccines expressing truncated and full length envelope protein. Vaccine. 2000;18(22):2426–34. doi: 10.1016/S0264-410X(99)00570-8.
    1. Simmons M, Burgess T, Lynch J, Putnak R. Protection against dengue virus by non-replicating and live attenuated vaccines used together in a prime boost vaccination strategy. Virology. 2010;396(2):280–288. doi: 10.1016/j.virol.2009.10.023.
    1. Maves RC, Ore RM, Porter KR, Kochel TJ. Immunogenicity and protective efficacy of a psoralen-inactivated dengue-1 virus vaccine candidate in Aotus nancymaae monkeys. Vaccine. 2011;29(15):2691–96. doi: 10.1016/j.vaccine.2011.01.077.
    1. Gozdek A, Zhukov I, Polkowska A, Poznanski J, Stankiewicz-Drogon A, Pawlowicz JM, et al. NS3 Peptide, a novel potent hepatitis C virus NS3 helicase inhibitor: Its mechanism of action and antiviral activity in the replicon system. Antimicrob Agents Chemother. 2008;52(2):393–401. doi: 10.1128/AAC.00961-07.
    1. Borowski P, Heising MV, Miranda IB, Liao CL, Choe J, Baier A. ViralNS3 helicase activity is inhibited by peptides reproducing the Arg-rich conserved motif of the enzyme (motif VI) Biochem Pharmacol. 2008;76(1):28–38. doi: 10.1016/j.bcp.2008.03.018.
    1. Lim SP, Noble CG, Shi PY. The dengue virus NS5 protein as a target for drug discovery. Antiviral Res. 2015;119:57–67. doi: 10.1016/j.antiviral.2015.04.010.
    1. Tuschl T. Expanding small RNA interference. Nat Biotechnol. 2002;20(5):446–448. doi: 10.1038/nbt0502-446.
    1. Alhoot MA, Wang SM, Sekaran SD. Inhibition of dengue virus entry and multiplication into monocytes using RNA interference. PLoS Negl Trop Dis. 2011;5(11):e1410. doi: 10.1371/journal.pntd.0001410.
    1. Zandi K, Teoh BT, Sam SS, Wong PF, Mustafa MR, Abubakar S. Antiviral activity of four types of bioflavonoid against dengue virus type-2. Virology J. 2011;8:560. doi: 10.1186/1743-422X-8-560.
    1. Talarico LB, Pujol CA, Zibetti RG, Faría PC, Noseda MD, Duarte ME, et al. The antiviral activity of sulfated polysaccharides against dengue virus is dependent on virus serotype and host cell. Antiviral Res. 2005;66(2–3):103–110. doi: 10.1016/j.antiviral.2005.02.001.
    1. Tang LI, Ling AP, Koh RY, Chye SM, Voon KG. Screening of anti-dengue activity in methanolic extracts of medicinal plants. BMC Complement Altern Med. 2012;12:3. doi: 10.1186/1472-6882-12-3.
    1. Monath TP. Dengue: The risk to developed and developing countries. Proc Natl Acad Sci U S A. 1994;91(7):2395–400. doi: 10.1073/pnas.91.7.2395.
    1. Rossi P, Ricci I, Cappelli A, Damiani C, Ulissi U, Mancini MV, et al. Mutual exclusion of Asaia and Wolbachia in the reproductive organs of mosquito vectors. Parasit Vectors. 2015;8:278. doi: 10.1186/s13071-015-0888-0.
    1. Mendes H: Brazil tests GM mosquitoes to fight Dengue. Males with offspring-killing genes are replacing wild insects, say researchers. 11 April 2012. .
    1. Hoffmann AA, Montgomery BL, Popovici J, Iturbe-Ormaetxe I, Johnson PH, Muzzi F, et al. Successful establishment of Wolbachia in Aedes populations to suppress dengue transmission. Nature. 2011;476(7361):454–7. doi: 10.1038/nature10356.
    1. McNaughton D, Duong TT. Designing a community engagement framework for a new dengue control method: a case study from central Vietnam. PLoS Negl Trop Dis. 2014;8(5):e2794. doi: 10.1371/journal.pntd.0002794.
    1. Alen MM, Schols D. Dengue virus entry as target for antiviral therapy. J Trop Med. 2012;2012:628475. doi: 10.1155/2012/628475.
    1. Nicholson CO, Costin JM, Rowe DK, Lin L, Jenwitheesuk E, Samudrala R, et al. Viral entry inhibitors block dengue antibody-dependent enhancement in vitro. Antiviral Res. 2011;89(1):71–74. doi: 10.1016/j.antiviral.2010.11.008.
    1. Courageot MP, Frenkiel MP, Duarte dos Santos CN, Deubel V, Desprès P. α-glucosidase inhibitors reduce dengue virus production by affecting the initial steps of virion morphogenesis in the endoplasmic reticulum. J Virol. 2000;74:564–572. doi: 10.1128/JVI.74.1.564-572.2000.
    1. Whitby K, Pierson TC, Geiss B, Lane K, Engle M, Zhou Y, et al. Castanospermine, a potent inhibitor of dengue virus infection in vitro and in vivo. J Virol. 2005;79(14):8698–8706. doi: 10.1128/JVI.79.14.8698-8706.2005.
    1. Alen MM, Kaptein SJ, De Burghgraeve T, Balzarini J, Neyts J, Schols D. Antiviral activity of carbohydrate binding agents and the role of DC-SIGN in dengue virus infection. Virology. 2009;387(1):67–75. doi: 10.1016/j.virol.2009.01.043.
    1. Lee E, Pavy M, Young N, Freeman C, Lobigs M. Antiviral effect of the heparan sulfate mimetic, PI-88, against dengue and encephalitic Flaviviruses. Antiviral Res. 2006;69(1):31–38. doi: 10.1016/j.antiviral.2005.08.006.
    1. Hidari KI, Takahashi N, Arihara M, Nagaoka M, Morita K, Suzuki T. Structure and anti-dengue virus activity of sulfated polysaccharide from a marine alga. Biochem Biophysic Res Comm. 2008;376(1):91–5. doi: 10.1016/j.bbrc.2008.08.100.
    1. Qiu H, Tang W, Tong X, Ding K, Zuo J. Structure elucidation and sulfated derivatives preparation of two α-dglucans from Gastrodia elata Bl. and their anti-dengue virus bioactivities. Carbohydr Res. 2007;342(15):2230–2236. doi: 10.1016/j.carres.2007.06.021.

Source: PubMed

Спонсоры и соавторы

Заболевания

Медикаментозные вмешательства

Подписаться